Results 81 to 90 of about 105,114 (279)
Advanced Science, EarlyView.This non‑enzymatic function of DHODH drives sunitinib resistance by competing with TRIM37 to block TRIM28 ubiquitination, thereby stabilizing TRIM28 and activating VEGFA transcription. Disrupting the DHODH–TRIM28 interaction with lisaftoclax restores drug sensitivity.
Shijie Qian +10 more
wiley +1 more source
Inactivation of XPF Sensitizes Cancer Cells to Gemcitabine
Journal of Nucleic Acids, 2019 Gemcitabine (2′, 2′-difluorodeoxycytidine; dFdC) is a deoxycytidine analog and is used primarily against pancreatic cancer. The cytotoxicity of gemcitabine is due to the inhibition of DNA replication.
Joseph W. George +2 more
doaj +1 more source
Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression. [PDF]
PLoS ONE, 2012 Although gemcitabine is highly active in several cancer types, intrinsic and acquired drug resistance remains a major challenge. Overexpression of Bcl-2 has been associated with gemcitabine resistance.
Foong Ying Wong +6 more
doaj +1 more source
Advanced Science, EarlyView.ANXA2+ sEVs promote cisplatin resistance in ATC by stabilizing the SRC/LDHA interaction, increasing LDHA phosphorylation and activity, and lactate production. Elevated lactate levels promote KAT5‐mediated lactylation of XRCC5 at lysine 265, enhancing its binding to XRCC6.
Shanshan Su +4 more
wiley +1 more source
, 2011 To evaluate the efficacy and safety profile of a triplet regimen consisting of gemcitabine, oxaliplatin, and infusional fluorouracil and leucovorin (LV) in advanced pancreatic carcinoma (APC).
CHANG, HUI-JU;HUANG, CHING-LUN;WANG, HSIU-PO;SHIAH, HER-SHYONG;CHANG, MING-CHU;JAN, CHANG-MING;CHEN, JEN-SHI;TIEN, YU-WEN;HWANG, TSANN-LONG;LIN, JAW-TOWN;CHENG, ANN-LII;WHANG-PENG, JACQUELINE;CHEN, LI-TZONG +1 more
core +1 more source
Advanced Science, EarlyView.A double‐layered shell‐core microneedle patch is developed to co‐deliver FOLFIRINOX, surufatinib, and anti‐PD‐1 for localized chemo‐immunotherapy of PDAC. This strategy achieves sustained tumor suppression, reduces metastasis, and reprograms the TME by enhancing CD8+ T‐cell infiltration and inhibiting Tregs and M2 macrophages infiltration, while ...
Tingting Kong +13 more
wiley +1 more source
Molecular Oncology, 2018 Gemcitabine serves as a first‐line chemotherapy agent for advanced pancreatic cancer (PC). However, the molecular basis by which gemcitabine exerts its effects is not well‐established, and the targeted genetic pathways remain unclear.
Lei You +9 more
doaj +1 more source
Advanced Science, EarlyView.This study established a high‐quality organoid biobank derived from 68 tumor sites across 50 Chinese patients, elucidated the drug sensitivity‐based molecular subtyping in breast cancer, and revealed a novel mechanism of drug resistance mediated by the FAK‐ACSL1 pathway.
Hao Xu +10 more
wiley +1 more source
Cancer Management and Research, 2017 Fadi Braiteh,1 Manish B Patel,2 Monika Parisi,2 Quanhong Ni,2 Siyeon Park,2,3 Claudio Faria2 1Comprehensive Cancer Centers of Nevada, University of Nevada School of Medicine, Las Vegas, NV, 2Celgene Corporation, Summit, NJ, 3The Ohio State University ...
Braiteh F +5 more
doaj
Sensitization of Pancreatic Cancer Stem Cells to Gemcitabine by Chk1 Inhibition
Neoplasia: An International Journal for Oncology Research, 2012 Checkpoint kinase 1 (Chk1) inhibition sensitizes pancreatic cancer cells and tumors to gemcitabine. We hypothesized that Chk1 inhibition would sensitize pancreatic cancer stem cells to gemcitabine.
Venkatasubbaiah A. Venkatesha +8 more
doaj +1 more source